U.S. Clinical Oncology Next Generation Sequencing (NGS) Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Single User License $3500

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Status : October, 2020 | Biotechnology | PPT format

Report Digest


U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Snapshot

With the advent of new technology, the potential that next generation sequencing (NGS) application holds in genetic counseling, disease management and treatment, and risk assessment is remarkable. From a clinical perspective, the technology can be applied to prenatal diagnosis, molecular diagnosis of genetic and infectious diseases, medical genetics and pharmacogenomics, carrier detection, cancer molecular diagnosis, and prognosis. 

In terms of technology, targeted sequencing and re-sequencing is a major contributor to the clinical oncology next generation sequencing market in the U.S. This technological segment will gain traction by enabling even higher throughput at reduced price per sample. Due to a decrease in the complexity of implementation, the use of whole genome sequencing (WGS) technology to make comparisons between tumor tissue and normal tissue is expected to witness a steep rise during the forecast period. In addition, researchers are of the opinion that through WSG everyone will be able to develop a personalized treatment plan. The segment is expected to grow further with the introduction of new tools such as NextSeq and MiniSeq platforms, which are likely to enhance the implement ability for a broad spectrum of research labs with varying sequencing needs. 

Based on end user, the U.S. market for clinical oncology next generation sequencing is segmented into pharmaceutical and biotech entities, clinical research, academic research institutes, and hospitals and clinics. Owing to growing awareness regarding the benefits associated with the implementation of second-generation sequencing in academic and university-based research projects, academic institutes will hold a strong presence in the clinical oncology next generation sequencing market. 

There are numerous players operating in the U.S. market. To hold their dominant position, many are banking on capitalizing data analysis requirements and need for more robust sequencing platforms through mergers and funding deals between major and minor players.  A case in point would be Partek collaborating with Kennedy Krieger Institute. Together they have developed a commercial software for analyzing chromosomal abnormalities in diseases such as autism spectrum disorder, bipolar disorder, and schizophrenia. 

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Overview

With continued enhancement of new sequencing technology, next-generation sequencing (NGS) is being increasingly used in cancer genomics research. Also known as massively parallel sequencing, these days NGS is being leveraged in clinical oncology to provide improved tailored therapy for cancer. Next generation sequencing finds application in detecting rare forms of cancer mutations, uncovering familial cancer mutation carriers, and in providing molecular rationale for the exact targeted therapy. Hence, it is widely considered as a disruptive technology in the area of cancer treatment. 

There have been many noteworthy achievements in the field of cancer genetics in the past couple of years on account of cutting-edge technologies and tanking costs of next-generation sequencing (NGS). The report by TMR Research offers key insights into the U.S. clinical oncology Next Generation Sequencing (NGS) market. It studies the degree of research and development in next generation sequencing for clinical oncology and furnishes crucial market figures from 2017 to 2025.

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Trends and Opportunities

Next generation sequencing has a number of advantages over traditional sequencing. First is its ability to completely sequence every kind of mutations for a large number of genes in one test cost-effectively. However, challenges exist in leveraging NGS, especially with respect to the need for simpler assays, more flexible throughput, reduced turnaround time, and most importantly in analyzing and interpreting the data. Overall, continued efforts to apply NGS in clinical oncology will take us one step closer to personalized medicine.

In the U.S., the clinical oncology next generation sequencing market has been buoyed by the astute initiatives of the government in the field of research and development in oncology. For example, loans and grants have been liberally disbursed by the U.S. government and various funding bodies to bring down the gap between genomic sequence analysis platforms development and their use in oncology research. In the near future, the substantial increase in spending related to cancer in the U.S. is slated to further drive up the demand for second generation sequencing platforms for diagnostic monitoring and theranostics applications.

A major challenge to the next generation sequencing is the time taken to uncover insights from the copious amount of data generated after the genome is sequenced. While this benefits the cancer patients as its aids in accurately studying many genes simultaneously that may be relevant to the patient’s tumor by using only a small amount of tissue at a reasonable cost, it also accords innumerable opportunities to commercial service providers to come up with proper solutions in much less time.

Companies Mentioned in Report

To present an in-depth assessment of the competition prevailing in the U.S. market for clinical oncology next generation sequencing, the report profiles companies such as Roche, llumina Inc., Pacific Bioscience, Agilent Technologies, GATC Biotech Ag, Macrogen Inc., Oxford Nanopore Technologies Ltd, Foundation Medicine, Life technologies Corp, Exosome Diagnostics, CLC Bio, Paradigm, Perkin Elmer, Inc, Inc, Partek, Inc, GnuBIO, and Caris Life Sciences. 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

This study provides a particularized anatomy according to the L.E.A.P mechanism

  • Latest trends and cardinal growth prospects
  • Existing and future insights in growth
  • Ascensions in technology
  • Pain points

The regional analysis offers market assays across:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.

Latest Trends and Cardinal Growth Prospects

The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.

Existing and Future Insights in Growth

The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.

Ascensions in Technology

Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.

Pain Points

The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.

The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.

An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.

The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!

This report is the key to questions such as:

What are the prominent factors that will help in reshaping the market growth?

Which trends have the potential to bring expansive growth for the market?

What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?

Which regions will emerge as champion growth contributors for the market?

Which aspects will serve as game-changers for the market?

What are the latest innovations in the market?

Which factors will hinder the growth of the market?